PARP Inhibitors in Recurrent Ovarian Cancer

In this downloadable slideset, CCO’s expert faculty reviews PARP inhibitors in the treatment of patients with recurrent ovarian cancer.
Ursula Matulonis, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.96 MB
Released: December 22, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
GlaxoSmithKline

Related Content

Expert commentary on the use of PARP inhibitors as frontline maintenance therapy in the treatment of ovarian cancer, from Clinical Care Options

Ursula Matulonis, MD Released: January 11, 2021

In this slideset, CCO’s expert faculty explores the role of biomarkers and HRD when treating patients with ovarian cancer using PARP inhibitors

person default Alexandra Leary, MD, PhD Released: December 22, 2020

CCO’s expert faculty reviews the different PARP inhibitors in the treatment of patients with newly diagnosed ovarian cancer.

Prof Ignace Vergote Released: December 22, 2020

CCO’s expert faculty reviews PARP inhibitor-associated adverse events, including identification and their management in newly diagnosed ovarian cancer.

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci Released: December 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue